Centessa Pharma ADR had its Relative Strength (RS) Rating upgraded from 85 to 92 Wednesday.
How To Use Stock Charts To Stay Profitable And Protected
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains often have an RS Rating of above 80 at the beginning of a new climb.
Centessa Pharma ADR is now considered extended and out of buy range after clearing an 18.14 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% EPS growth in its most recent report. Sales increased -100%.
Centessa Pharma ADR earns the No. 4 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
